The infant formula necrotizing enterocolitis (NEC) MDL has moved through a complicated spring. Federal bellwether outcomes have favored the manufacturers so far; state court juries have moved decisively the other way; and the next federal trial — the first one against Mead Johnson — is now scheduled. This is a plain-English read on where the litigation stands as of June 2026 and what it means for families with pending claims or considering a case.
Where the Cases Sit Right Now
As of late May 2026, approximately 797 active cases were pending in MDL 3026 — the In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation — before U.S. District Judge Rebecca Pallmeyer in the Northern District of Illinois. The MDL consolidates federal cases against the two major manufacturers of premature infant formula, Abbott (which makes the Similac line) and Reckitt Benckiser's Mead Johnson subsidiary (which makes the Enfamil line).
State court cases against the same defendants are running on a parallel track, primarily in Illinois (Cook County), Missouri, and other plaintiff-friendly jurisdictions. The state and federal tracks have produced very different results so far, which we cover below.
Federal Bellwether Picture: Three Abbott Wins, One Mead Johnson Loss on Summary Judgment
The federal bellwether process — the small group of representative test cases that go to trial first to give both sides a read on jury behavior — has produced mixed results for plaintiffs at the threshold stage:
- Abbott has won the first three federal bellwether cases on summary judgment. In each instance, the court found that the plaintiff had not presented enough evidence to send the case to a jury. Plaintiffs have appealed.
- Mead Johnson's summary judgment motion was denied in the first federal bellwether case targeting its Enfamil Premature formula. The Illinois federal judge ruled that the case can proceed to trial — meaning a jury will hear the evidence.
The Abbott summary judgment wins are significant. Summary judgment is the legal device that lets a court dismiss a case before trial if the evidence is too thin for a reasonable jury to find for the plaintiff. Three back-to-back rulings on that issue against Abbott plaintiffs suggest the court has identified specific evidentiary gaps in the federal cases against Abbott that did not exist (or did not survive challenge) against Mead Johnson.
What this does not mean: that all NEC cases against Abbott are doomed. The federal bellwethers are a small set of test cases, and the issues that decided them may not apply to the broader pool. Plaintiffs' counsel are reviewing the rulings carefully for what evidence and expert testimony the next round of cases needs to include.
The Inman v. Mead Johnson Trial: August 2026
The next major federal trial in the MDL is Inman v. Mead Johnson & Company, LLC, et al., currently set for August 2026. This will be the first federal bellwether trial in MDL 3026 against Mead Johnson — and the first chance for a federal jury to weigh the evidence on Enfamil Premature formula and NEC.
The Inman case matters for several reasons:
- It is the first time the Mead Johnson evidence will be presented to a jury in the federal forum, rather than dismissed at the summary judgment stage.
- The verdict (whichever way it goes) will give both sides real signal on how juries weigh the Enfamil-specific science and warnings record.
- A plaintiff win would create pressure for global settlement discussions with Mead Johnson.
- A defense win would prolong the litigation and require plaintiffs to develop additional evidence or theories for subsequent trials.
The trial schedule may shift — bellwether dates often do — but August 2026 is the current target on the court's calendar.
The State Court Picture: Very Different Story
While federal bellwethers have favored the manufacturers, state court juries have done the opposite. In April 2026, a Chicago jury returned a verdict for four plaintiff families in a consolidated Illinois state court trial against Abbott. In July 2024, a Missouri jury also returned a substantial verdict for plaintiffs against the formula makers.
We do not publish individual case verdict amounts on this site. What matters for families with pending or potential claims is the directional signal: state court juries, presented with the Enfamil and Similac science and the corporate documents, have repeatedly found for the families. That is a meaningful counterweight to the federal summary judgment record.
Why the venues split matters. State courts and federal courts can apply somewhat different procedural rules, admit somewhat different evidence, and select juries from different population pools. A case's likely value can depend significantly on whether it lands in state or federal court. This is part of the strategic conversation families should have with counsel before filing.
What This Means for Families
If your premature baby developed NEC after being fed Abbott Similac or Mead Johnson Enfamil formula in the NICU, the current state of the litigation has a few specific implications:
- The federal bellwether wins for Abbott do not close the door. They identify the specific evidentiary issues that need to be addressed in the broader pool, but they do not bind cases that have stronger or different evidence.
- The Mead Johnson side is moving toward trial. If your case involves Enfamil specifically, the August 2026 Inman trial will be the first real jury read.
- State court filing may make sense in some cases. Which court your case belongs in depends on jurisdictional rules, the defendants involved, and where the harm occurred. Our companion guide on state-by-state NEC filing deadlines covers the basics.
- Filing windows are still running. NEC cases use state product liability statutes of limitations, which generally run from the date the family knew (or reasonably should have known) about the link between formula and NEC. Each state's discovery rule is different, and the clock does not pause for the MDL.
- No global settlement has been announced. Despite the state court verdicts and the upcoming federal trials, there has been no settlement framework offered to the broader pool of cases. Families considering claims should not wait for a settlement to file.
What to Watch the Rest of 2026
- The Inman v. Mead Johnson trial in August. First federal jury verdict in the MDL against Mead Johnson.
- Appeals of the Abbott summary judgment rulings. The Seventh Circuit's view of the court's threshold rulings could reshape the federal Abbott pool.
- Additional state court trials. Illinois and Missouri state courts have additional NEC cases on their calendars. Each verdict adds to the negotiation backdrop.
- Possible settlement discussions. A meaningful federal trial loss for either Mead Johnson or Abbott would likely trigger settlement talks. Families should be in a position to participate in those discussions if they happen.
If You Are Considering a Case
If your premature baby developed NEC after receiving cow's-milk-based formula in the NICU, the free case review is structured around two early questions: (1) is the medical timeline consistent with a viable formula-NEC case, and (2) is your state's filing window still open?
- See if your situation fits the case profile: Do I qualify for an NEC lawsuit?
- Understand the underlying science: Why cow's-milk-based formula causes NEC.
- Read the warning signs that may have been missed: Signs of NEC in premature babies.
- Identify which formula was given: Was your baby on Similac or Enfamil?
Free case review. No Fees Unless We Recover Money for You.
Sources
- U.S. Judicial Panel on Multidistrict Litigation — MDL 3026 docket and statistics. jpml.uscourts.gov
- U.S. District Court, Northern District of Illinois — Judge Rebecca Pallmeyer chambers and MDL 3026 case management orders. ilnd.uscourts.gov
- BusinessWire / Levin Papantonio — "Trial Set in NEC Multidistrict Litigation Against Reckitt Benckiser's Mead Johnson" (Inman v. Mead Johnson trial setting). businesswire.com
- MDL Update — "Baby Formula NEC Lawsuit MDL-3026 May 2026 MDL Update." mdlupdate.com
- Verus LLC — "Infant Formula Lawsuit Update" (MDL 3026 case management coverage). verusllc.com
- U.S. Food & Drug Administration — Premature infant nutrition and infant formula guidance. fda.gov
- National Institutes of Health / National Library of Medicine — peer-reviewed research on cow's-milk-based formula and NEC in preterm infants. ncbi.nlm.nih.gov